US 11,926,600 B2
Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
Matthew Cooper, Cambridge (GB); David Miller, Cambridge (GB); Angus MacLeod, Cambridge (GB); Stephen Thom, Nottingham (GB); Stephen St-Gallay, Nottingham (GB); and Jonathan Shannon, Nottingham (GB)
Assigned to INFLAZOME LIMITED, Dublin (IE)
Appl. No. 16/638,700
Filed by Inflazome Limited, Dublin (IE)
PCT Filed Aug. 15, 2018, PCT No. PCT/EP2018/072125
§ 371(c)(1), (2) Date Feb. 12, 2020,
PCT Pub. No. WO2019/034693, PCT Pub. Date Feb. 21, 2019.
Claims priority of application No. 1713082 (GB), filed on Aug. 15, 2017; application No. 1718563 (GB), filed on Nov. 9, 2017; application No. 1721726 (GB), filed on Dec. 22, 2017; application No. 1721735 (GB), filed on Dec. 22, 2017; and application No. 1810983 (GB), filed on Jul. 4, 2018.
Prior Publication US 2021/0122716 A1, Apr. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 233/84 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 405/06 (2006.01)
CPC C07D 233/84 (2013.01) [C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 405/06 (2013.01)] 12 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof, wherein:
R1 is an imidazolyl group, wherein the imidazolyl group is an imidazol-2-yl group, an imidazol-4-yl group or an imidazol-5-yl group, and wherein the imidazolyl group is substituted with one or more monovalent substituents; and
R2 is a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group is substituted at the α and α′ positions, and wherein R2 may optionally be further substituted.